This is an author correction of an article published in Nature Medicine on January 28, 2026 with doi: 10.1038/s41591-026-04233-9. The article concerns a phase 3b open-label study of the intrathecal administration of the onasemnogen abeparvoveca in treatment-experienced patients with spinal muscular atrophy (SMA). The study is investigating this drug administered directly into the spinal cord in already treated patients. This is an author's correction of the original scientific text. No other details about the results or statistics are given in the content provided.